NLS Pharmaceutics AG
NLSP
$1.53
$0.0553.74%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 891.10K | 891.10K | 1.37M | 1.37M | 1.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.03M | 1.03M | 2.13M | 2.13M | 3.77M |
| Operating Income | -1.03M | -1.03M | -2.13M | -2.13M | -3.77M |
| Income Before Tax | -1.02M | -1.02M | -2.28M | -2.28M | -3.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.02M | -1.02M | -2.28M | -2.28M | -3.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.02M | -1.02M | -2.28M | -2.28M | -3.81M |
| EBIT | -1.03M | -1.03M | -2.13M | -2.13M | -3.77M |
| EBITDA | -1.02M | -1.02M | -2.13M | -2.13M | -3.77M |
| EPS Basic | -0.97 | -0.97 | -2.39 | -2.39 | -3.99 |
| Normalized Basic EPS | -0.61 | -0.61 | -1.49 | -1.49 | -2.49 |
| EPS Diluted | -0.97 | -0.97 | -2.39 | -2.39 | -3.99 |
| Normalized Diluted EPS | -0.61 | -0.61 | -1.49 | -1.49 | -2.49 |
| Average Basic Shares Outstanding | 1.05M | 1.05M | 954.40K | 954.40K | 954.40K |
| Average Diluted Shares Outstanding | 1.05M | 1.05M | 954.40K | 954.40K | 954.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |